BLOODSCAN
 |  |  |  |  |  |
|---|---|---|---|---|---|
 |  |  |
BLOODSCAN
Welcome to Bloodscan, where innovation meets precision. Harnessing the power of the Labyrinth Microfluidic System, we're pioneering non-invasive techniques for cancer detection and disease monitoring. Dive in to discover our groundbreaking research and how we're shaping the future of biotechnology.
OUR STORY
The Labyrinth microfluidic chip, a pioneering technology developed at the University of Michigan, represents a significant advancement in the field of Circulating Tumor Cell (CTC) enrichment. This groundbreaking technology is designed to enrich CTCs in a label-free, high-throughput, and live-cell manner, setting a new standard for efficiency and effectiveness in the field. Since its inception, the Labyrinth microfluidic chip has rapidly gained recognition and is now celebrated as one of the foremost methods of CTC enrichment in academic circles.
Born from this academic excellence, Bloodscan emerged as a spin-off company with a singular mission: to bring the Labyrinth microfluidic system to the forefront of cancer diagnostics and make it accessible to a broader audience. Our dedication to this cause has been unwavering. After years of meticulous development and refinement, we are on the cusp of a significant milestone. The commercial version of our Labyrinth automated CTC processor is slated for launch in early 2024. This state-of-the-art system promises to offer the public a truly cost-effective, hassle-free, and high-performance solution in the fight against cancer.
Our Team
Bloodscan is anchored by a team with unparalleled expertise in biomedical engineering and tumor cell detection, rooted in institutions like the University of Michigan and Harvard. Our pioneering innovations in CTC microfluidic technology are complemented by decades of entrepreneurial success and strategic networking across industries. With a unique blend of scientific rigor, business acumen, and deep connections in the medical sector, Bloodscan is poised to lead the revolution in non-invasive cancer diagnostics.
Technology
Labyrinth microfluidic chip has been applied in various academic and clinical studies to enable downstream applications through its high CTC purity, viability, recovery, and unbiased enrichment.
Disease screening
Early detection and disease monitoring
Tumor biology
Molecular characterization, therapy targets and resistance mechanisms
Personalized medicine
Identification of actionable targets and therapeutic trials
Featured Publications
Discover key peer-reviewed publications that spotlight the groundbreaking work of scientists harnessing the Labyrinth microfluidic system.